Dyne Therapeutics, Inc. Cash Flow Statement
DYN / Health Care|6 years of annual SEC 10-K data (FY2019-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Dyne Therapeutics, Inc. used $292M in operating cash flow and negative free cash flow of $295M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|
| Net Income | -$317.4M | -$235.9M | -$168.1M | -$149.3M | -$59.4M | -$14.9M |
| Depreciation & Amortization | $1.7M | $1.7M | $1.7M | $1.1M | $700.0K | $271.0K |
| Operating Cash Flow | -$292.4M | -$188.2M | -$153.6M | -$119.6M | -$46.5M | -$11.8M |
| Capital Expenditures | $2.4M | $729.0K | $3.1M | $3.6M | $1.2M | $1.6M |
| Free Cash Flow | -$294.7M | -$188.9M | -$156.7M | -$123.2M | -$47.7M | -$13.5M |